AKTS.US Aktis Oncology, Inc. Common stock

Healthcare Biotechnology USA Stocks
17.20 USD
Close of Nov 14, 2026
13.96 34.19
Market cap
USD 924M
P/E
-
P/B
1.87x
ROE
-21.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is AKTS.US undervalued?

Graham number

The Graham number of Aktis Oncology, Inc. Common stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Aktis Oncology, Inc. Common stock fundamental analysis

No fundamental analysis for Aktis Oncology, Inc. Common stock yet.

Aktis Oncology, Inc. Common stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Aktis Oncology, Inc. Common stock

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colore…

Full company profile